|
gptkbp:instanceOf
|
gptkb:chemical_compound
antineoplastic agent
World Health Organization essential medicine
platinum-based drug
|
|
gptkbp:approvedBy
|
1978
|
|
gptkbp:ATCCode
|
L01XA01
|
|
gptkbp:CASNumber
|
15663-27-1
|
|
gptkbp:chemicalFormula
|
Cl2H6N2Pt
|
|
gptkbp:color
|
yellow
|
|
gptkbp:crystalSystem
|
orthorhombic
|
|
gptkbp:discoveredBy
|
gptkb:Michele_Peyrone
|
|
gptkbp:discoveredIn
|
gptkb:Italy
1845
|
|
gptkbp:eliminationHalfLife
|
20–30 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstClinicalUse
|
1971
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cisplatin
|
|
gptkbp:isomerOf
|
gptkb:transplatin
|
|
gptkbp:IUPACName
|
gptkb:cis-diamminedichloroplatinum(II)
|
|
gptkbp:KEGGID
|
D00275
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
DNA crosslinking
inhibition of DNA synthesis
|
|
gptkbp:meltingPoint
|
270 °C (decomposes)
|
|
gptkbp:metabolism
|
non-enzymatic
|
|
gptkbp:molecularWeight
|
300.05 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
CHEMBL1377
441203
CHEBI:27899
DB00515
|
|
gptkbp:relatedTo
|
gptkb:carboplatin
gptkb:oxaliplatin
gptkb:nedaplatin
gptkb:satraplatin
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
nephrotoxicity
neurotoxicity
ototoxicity
myelosuppression
electrolyte disturbances
|
|
gptkbp:solubility
|
2.53 g/L (25 °C)
|
|
gptkbp:UNII
|
Q20Q21Q62J
|
|
gptkbp:usedForTreatmentOf
|
gptkb:cancer
colorectal cancer
esophageal cancer
testicular cancer
bladder cancer
head and neck cancer
gastric cancer
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|